To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.8052563.
Pain is a terrible health problem that transcends borders and nationalities, although there may be significant differences among regions regarding pain management. In Latin America (LatAm, composed of the many nations of Central America, South America, Mexico, and the Caribbean), access to healthcare, pain management, and opioid analgesics can vary. Despite an international U.S.-led trend toward greater control in opioid prescribing, the role of opioids in the management of severe pain in LatAm is probably smaller than it should be, as opioid consumption in LatAm overall is low. Buprenorphine is a strong opioidwith certain characteristics that make it a potentially useful analgesic agent in LatAm: it has a unique pharmacology that allows for transdermal administration and a favorable safety profile with a ceiling effect for respiratory depression. It has a well-studied low risk potential for misuse, and there is strong evidence for its safety and efficacy in managing both cancer and noncancer pain in adults. Caregivers and policy makers in LatAm may learn from the U.S. experience with opioids in order to develop protocols to better and safely manage pain, and it is possible that buprenorphine will play a key role.
Norris ET, Wang L, Conley AB, et al. Genetic ancestry, admixture and health determinants in Latin America. BMC Genom. 2018;19(Suppl 8):861.
Williams R, Long J, Hanson R, Sievers M, Knowler W. Individual estimates of European admixture associated with lower body-mass index, plasma glucose, and prevalence of types 2 diabetes in Pima Indians. Am J Hum Genet. 2000;66:527–38. PubMed
World Bank. News: Universal healthcare on the rise in Latin America. 2013. http://www.worldbank.org/en/news/feature/2013/02/14/universal-healthcare-latin-america. Accessed Dec 20, 2018.
Atun R, de Andrade LO, Almeida G, et al. Health-system reform and universal health coverage in Latin America. Lancet (London, England). 2015;385(9974):1230–47.
Ernst Young. Latin American insurance outlook. 2017. https://www.ey.com/Publication/vwLUAssets/ey-2017-latin-american-insurance-outlook/$FILE/ey-2017-latin-american-insurance-outlook.pdf. Accessed 13 May 2019.
Ramirez J. These are the five health challenges facing Latin America. 2016. https://www.weforum.org/agenda/2016/06/these-are-the-5-health-challenges-facing-latin-america/. Accessed 20 Dec 2018.
McCarthy M. Boom in Latin American and Caribbean elderly population. Region’s health systems have 10 years to prepare for rising number of elderly, report warns. Lancet. 2004;363(9407):458–9. PubMed
Rodriguez T, Malvezzi M, Chatenoud L, et al. Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970–2000. Heart (British Cardiac Society). 2006;92(4):453–60.
Bardach A, Perdomo HA, Gandara RA, Ciapponi A. Income and smoking prevalence in Latin America: a systematic review and meta-analysis. Pan Am J Publ Health. 2016;40(4):263–71.
Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–96.
Narouze S, Souzdalnitski D. Obesity and chronic pain: systematic review of prevalence and implications for pain practice. Reg Anesth Pain Med. 2015;40(2):91–111. PubMed
Hozumi J, Sumitani M, Matsubayashi Y, et al. Relationship between neuropathic pain and obesity. Pain Res Manag. 2016;2016:2487924.
Garcia CA, Santos Garcia JB, Rosario MD, et al. Undertreatment of pain and low use of opioids in Latin America. Pain Manag. 2018;8(3):181–96. PubMed
Lara-Solares A, Aguayo Zamora C, Amescua Garcia C, et al. Latin-American guidelines for opioid use in chronic nononcologic pain. Pain Manag. 2017;7(3):207–15. PubMed
World Health Organization. WHO’s pain ladder for adults. 1988. http://www.who.int/cancer/palliative/painladder/en/. Accessed 7 May, 2013.
Mitra R, Jones S. Adjuvant analgesics in cancer pain: a review. Am J Hospice Palliat Care. 2012;29(1):70–9.
Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014;32(16):1677–90. PubMed
Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2013;7:CD003868.
LeQuang J, Pergolizzi J. Chemotherapy-induced peripheral neuropathy: review of clinical studies. Boca Raton: CRC Press; 2012.
van Helmond N, Timmerman H, van Dasselaar NT, et al. High body mass index is a potential risk factor for persistent postoperative pain after breast cancer treatment. Pain Phys. 2017;20(5):E661–71.
Garcia J. Change Pain Latin America—new initiative established to enhance management of patients with chronic pain in Latin America. Braz J Anesthesiol. 2014;64:140–2.
Cleary J, De Lima L, Eisenchlas J, Radbruch L, Torode J, Cherny NI. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Latin America and the Caribbean: a report from the Global Opioid Policy Initiative (GOPI). Ann Oncol. 2013;24(Suppl 11):xi41-50. PubMed
Ruiz Iban MA, Benavides J, Forero JP, et al. Use of strong opioids for chronic pain in osteoarthritis: an insight into the Latin American reality. Expert Rev Clin Pharmacol. 2018;11(1):47–59. PubMed
De Lima L, Pastrana T. Evaluation of the effectiveness of workshops on the availability and rational use of opioids in Latin America. J Palliat Med. 2016;19(9):964–71. PubMed
Wesson DR, Smith DE. Buprenorphine in the treatment of opiate dependence. J Psychoactive Drugs. 2010;42(2):161–75. PubMed
Pergolizzi JV Jr, Scholten W, Smith KJ, Leighton-Scott J, Willis JC, Henningfield JE. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan. 2015;53(2):71–6. PubMed
Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005;29(3):297–326. PubMed
Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl. 2003;133:9–14 (discussion 23-14).
Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract. 2010;10(5):428–50. PubMed
Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med. 2006;20(Suppl 1):s3–8. PubMed
Zacny JP, Conley K, Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther. 1997;282(3):1187–97. PubMed
Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality. Part II. Psychosomatics. 2003;44(6):515–20. PubMed
DePriest AZ, Puet BL, Holt AC, Roberts A, Cone EJ. Metabolism and disposition of prescription opioids: a review. Forensic Sci Rev. 2015;27(2):115–45. PubMed
Brown S, Holtzman MJ, Kim TH, Kharasch E. Buprenorphine metabolites, buprenorphine-3-glucuronide and norbupenorphine-3-glucuronide, are biologically active. Anesthesiology. 2011;115:1251–60.
Moody DE, Slawson MH, Strain EC, Laycock JD, Spanbauer AC, Foltz RL. A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem. 2002;306(1):31–9. PubMed
Ohtani M, Kotaki H, Sawada Y, Iga T. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther. 1995;272(2):505–10. PubMed
Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther. 1997;281(1):428–33. PubMed
Huang P, Kehner GB, Cowan A, Liu-Chen LY. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001;297(2):688–95. PubMed
Pergolizzi J, Raffa R, Taylor R. Low-dose transdermal buprenorphine system: an update. Pain Eur. 2012;1:8–9.
Plosker GL. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs. 2011;71(18):2491–509. PubMed
Uberall MA, Muller-Schwefe GH. Long-term treatment of chronic pain with low-dose 7-day buprenorphine transdermal patch. Observational data from elderly patients of pain relief and quality of life. MMW Fortschr Med. 2013;155(Suppl 3):87–96.
Breivik H, Ljosaa TM, Stengaard-Pedersen K, et al. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids. Scand J Pain. 2010;1(3):122–41. PubMed
Gatti A, Dauri M, Leonardis F, et al. Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain. Clin Drug Investig. 2010;30(Suppl 2):31–8. PubMed
Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther. 2009;31(3):503–13. PubMed
Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study. J Pain. 2011;12(11):1163–73. PubMed
Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naive patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2011;42(6):903–17. PubMed
Leng X, Li Z, Lv H, et al. Effectiveness and safety of transdermal buprenorphine versus sustained-release tramadol in patients with moderate to severe musculoskeletal pain: an 8-week, randomized, double-blind, double-dummy, multicenter, active-controlled, noninferiority study. Clin J Pain. 2015;31(7):612–20. PubMed
Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther. 2010;32(5):844–60. PubMed
Conaghan PG, O’Brien CM, Wilson M, Schofield JP. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage. 2011;19(8):930–8. PubMed
Yoon DH, Bin SI, Chan SK, et al. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. BMC Musculoskelet Dis. 2017;18(1):337.
Yarlas A, Miller K, Wen W, et al. Buprenorphine transdermal system improves sleep quality and reduces sleep disturbance in patients with moderate-to-severe chronic low back pain: results from two randomized controlled trials. Pain Pract. 2015;16:345–58. PubMed
Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids. Ann Oncol. 2016;27(6):1107–15. PubMed
Nosek K, Leppert W, Nosek H, Wordliczek J, Onichimowski D. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. Drug Des Dev Ther. 2017;11:2409–19.
Schmidt-Hansen M, Taubert M, Bromham N, Hilgart JS, Arnold S. The effectiveness of buprenorphine for treating cancer pain: an abridged Cochrane review. BMJ Support Palliat Care. 2016;6(3):292–306. PubMed
Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice—a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin. 2005;21(8):1147–56. PubMed
Wen W, Lynch SY, Munera C, Swanton R, Ripa SR, Maibach H. Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis. Expert Opin Drug Saf. 2013;12(3):309–19. PubMed
Cooper TE, Fisher E, Gray AL, et al. Opioids for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev (Online). 2017;7:2538.
Ruggiero A, Coccia P, Arena R, et al. Efficacy and safety of transdermal buprenorphine in the management of children with cancer-related pain. Pediatr Blood Cancer. 2013;60(3):433–7. PubMed
Attina G, Ruggiero A, Maurizi P, Arlotta A, Chiaretti A, Riccardi R. Transdermal buprenorphine in children with cancer-related pain. Pediatr Blood Cancer. 2009;52(1):125–7. PubMed
Pergolizzi JV, Raffa RB, Marcum Z, Colucci S, Ripa SR. Safety of buprenorphine transdermal system in the management of pain in older adults. Postgrad Med. 2017;129(1):92–101. PubMed
Uberall MA, Muller-Schwefe GH. Low-dose 7-day transdermal buprenorphine in daily clinical practice—perceptions of elderly patients with moderate non-malignant chronic pain. Curr Med Res Opin. 2012;28(10):1585–95. PubMed
Al-Tawil N, Odar-Cederlof I, Berggren AC, Johnson HE, Persson J. Pharmacokinetics of transdermal buprenorphine patch in the elderly. Eur J Clin Pharmacol. 2013;69(2):143–9. PubMed
Brennan F, Carr DB, Cousins M. Pain management: a fundamental human right. Anesth Analg. 2007;105(1):205–21. PubMed
Daher M. Pain relief is a human right. Asian Pac J Cancer Prevent APJCP. 2010;11(Suppl 1):97–101.
Hooley JM, Franklin JC, Nock MK. Chronic pain and suicide: understanding the association. Curr Pain Headache Rep. 2014;18(8):435. PubMed
Nalamachu SR. Opioid rotation in clinical practice. Adv Ther. 2012;29(10):849–63. PubMed
Pergolizzi JV Jr, Gharibo C, Passik S, et al. Dynamic risk factors in the misuse of opioid analgesics. J Psychosom Res. 2012;72(6):443–51. PubMed
- Pain Control in Latin America: The Optimized Role of Buprenorphine in the Treatment of Cancer and Noncancer Pain
Joseph V. Pergolizzi Jr.
Robert Taylor Jr.
Jo Ann LeQuang
Andres Hernandez Ortiz
Miguel A. Ruiz Iban
- Springer Healthcare
Pain and Therapy
Print ISSN: 2193-8237
Elektronische ISSN: 2193-651X
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II